---
figid: PMC5507646__onco12134-fig-0001
figtitle: BRAF mutations in the context of mitogen‐activated protein kinase (MAPK)
  molecular alterations
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC5507646
filename: onco12134-fig-0001.jpg
figlink: /pmc/articles/PMC5507646/figure/onco12134-fig-0001/
number: F1
caption: 'BRAF mutations in the context of mitogen‐activated protein kinase (MAPK)
  molecular alterations. The approximate observed frequencies of common driver mutations
  in the MAPK pathway in lung cancer are shown on the left of the figure. BRAF valine
  at codon 600 (V600E) mutations leading to constitutive activation of BRAF are relatively
  rare, occurring in 1%–2% of lung cancers. For patients with activating BRAF mutations,
  direct inhibition of BRAF alone or in combination with downstream MEK inhibition
  is currently under clinical evaluation. Notable BRAF and MEK inhibitors under development
  are depicted on the right.Abbreviations: BRAF, B‐Raf proto‐oncogene, serine/threonine
  kinase; EGFR, epidermal growth factor receptor; ERK, extracellular signal‐regulated
  kinase; HER2, human epidermal growth factor receptor 2; KRAS, KRAS proto‐oncogene,
  GTPase; MEK, mitogen‐activated protein kinase kinase; MET, MET proto‐oncogene, receptor
  tyrosine kinase; NRAS, NRAS proto‐oncogene, GTPase; ROS, ROS proto‐oncogene 1, receptor
  tyrosine kinase.'
papertitle: 'Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling
  to Rationally Designed Therapy.'
reftext: Christina S. Baik, et al. Oncologist. 2017 Jul;22(7):786-796.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9410593
figid_alias: PMC5507646__F1
figtype: Figure
redirect_from: /figures/PMC5507646__F1
ndex: 4c0e5dc3-df02-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5507646__onco12134-fig-0001.html
  '@type': Dataset
  description: 'BRAF mutations in the context of mitogen‐activated protein kinase
    (MAPK) molecular alterations. The approximate observed frequencies of common driver
    mutations in the MAPK pathway in lung cancer are shown on the left of the figure.
    BRAF valine at codon 600 (V600E) mutations leading to constitutive activation
    of BRAF are relatively rare, occurring in 1%–2% of lung cancers. For patients
    with activating BRAF mutations, direct inhibition of BRAF alone or in combination
    with downstream MEK inhibition is currently under clinical evaluation. Notable
    BRAF and MEK inhibitors under development are depicted on the right.Abbreviations:
    BRAF, B‐Raf proto‐oncogene, serine/threonine kinase; EGFR, epidermal growth factor
    receptor; ERK, extracellular signal‐regulated kinase; HER2, human epidermal growth
    factor receptor 2; KRAS, KRAS proto‐oncogene, GTPase; MEK, mitogen‐activated protein
    kinase kinase; MET, MET proto‐oncogene, receptor tyrosine kinase; NRAS, NRAS proto‐oncogene,
    GTPase; ROS, ROS proto‐oncogene 1, receptor tyrosine kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - egfra
  - ros1
  - her2
  - pak2a
  - itpka
  - kita
  - ngfra
  - kras
  - rab1ab
  - nras
  - braf
  - si:dkey-222f8.3
  - map2k1
  - EGFR
  - ROS1
  - ERBB2
  - GZMM
  - KRAS
  - NRAS
  - HRAS
  - BRAF
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - Selumetinib
  - Trametinib
  - Dabrafenib
  - Cobimetinib
  - Binimetinib
  - tyrosine
  - Cancer
  - Lung cancer
---
